Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy - Wikidata - wikimedia - TriplyDB

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

http://www.wikidata.org/entity/Q24596055

about

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients Harnessing the immune system to improve cancer therapy Checkpoint Inhibitors and Their Application in Breast Cancer Adoptive immunotherapy against ovarian cancer Immunotherapy for cancer in the central nervous system: Current and future directions Cancer immunotherapy: the beginning of the end of cancer?Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)Updates in Therapy for Advanced Melanoma Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor Immunity T-Cell Therapy: Options for Infectious Diseases Immunotherapy of Childhood Sarcomas Strategies for combining immunotherapy with radiation for anticancer therapy Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy Reflections on the Histopathology of Tumor-Infiltrating Lymphocytes in Melanoma and the Host Immune Response The Evolution of T-cell Therapies for Solid Malignancies Adoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergy Acquired and intrinsic resistance in cancer immunotherapy T lymphocytes targeting native receptors Immune reconstitution in chronic lymphocytic leukemia Pathways and therapeutic targets in melanoma Primer on tumor immunology and cancer immunotherapy Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook Novel immunotherapies for hematologic malignancies Adoptive T-cell therapy for Leukemia Toxicities of Immunotherapy for the Practitioner Potential for immunotherapy in soft tissue sarcoma Adoptive cell therapy for sarcoma γδ T cells for cancer immunotherapy: A systematic review of clinical trials The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment Bone specific immunity and its impact on metastasis CD4 T-cell immunotherapy for chronic viral infections and cancer Current translational and clinical practices in hematopoietic cell and gene therapy Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges Targeting the tumor vasculature to enhance T cell activity Genetically modified T cells in cancer therapy: opportunities and challenges Lineage relationship of effector and memory T cells Proliferation-linked apoptosis of adoptively transferred T cells after IL-15 administration in macaques

P2860

Q24598792-DAAFB73D-23EA-4103-B7F7-81D915A7ED35 Q26738698-F65209C0-9D92-4CF1-9543-16E24B13AA5C Q26745442-BBDEDA03-9B43-490A-B872-4D86F3B896A7 Q26748905-26EBDB1F-F311-4345-8BF5-B07817E8875A Q26750765-AEA40DD3-0313-40A9-9977-FDE0BA9658A4 Q26752277-3941F815-8CD9-4FB5-9E39-BA92E45E2F91 Q26765429-AA43909C-8D49-4C89-B8E7-39A70F68B348 Q26771119-6EF8693C-08D4-416A-91B0-3C27CC5FEDCC Q26773309-367F82F2-A9B5-47A0-9FF8-9A8B94E6E2EB Q26774669-632F114E-1240-4E7C-98F3-ED71D9115852 Q26782201-34A91784-8F25-49B3-8D25-EC9F24DE024B Q26786661-B59AEF6E-C180-4A53-BE22-2B77258AC683 Q26795369-CE718D13-BA57-4CE0-A6DB-018E3F5E892B Q26796675-DDA1838D-9719-4400-9E50-07155069B550 Q26798404-FB208A94-FB45-4C9E-BEC6-C8E8C2407F47 Q26799073-D3C839BE-2905-49D5-BCB9-2CF38A90929E Q26799372-4FF39CDE-ABC7-433E-BD35-6BF8C3749DA1 Q26822793-1E2A5B40-57A3-485F-952C-FFA0A1E479E9 Q26827701-8AFAD0F2-6891-41A8-8382-11D1A3CE50F0 Q26853345-80908F95-12D8-4A6D-826E-D88967A0B1A6 Q26865561-0E93AF20-EE60-438E-B546-9B06983A5FDB Q26865736-535D326D-892D-43E2-8350-73BBC6919CFC Q27001126-A54DBE40-96F9-4F15-92BD-9D770F0FF5D8 Q27002575-741C1D1C-A01B-43EF-906A-B129F726AEBF Q27004178-4993F86E-4376-4C9D-A62B-AF48416FD140 Q27004436-D832192F-E382-427C-B60A-B486EF9FD462 Q27006934-A408A461-3C3B-4813-AA18-2DC42D8E45B2 Q27008140-2ED3C385-C28E-45ED-B1F4-DC2CFF86BF52 Q27008830-A1214919-0C05-47CF-8BC6-2DC5C4238AF4 Q27009541-FE6F93EB-2E3D-473D-85D9-1320C6C982CC Q27021705-27397CC8-9196-43C0-A300-B5CDCEF247BF Q27022789-4F2D9048-E3C7-4512-88DC-93DB5F5127A5 Q27022883-C11ED323-6569-4043-9F71-6BE7924353E2 Q27022957-8AADD02A-0BB1-43BA-8630-6E00D958E753 Q27024456-DAA9E863-13C3-4911-896D-007714C1CF27 Q27025300-B6212C1E-5662-4BA9-9C08-082E5D8113E0 Q27026329-764B9884-78D9-4BC2-9FBA-76072FEFB0A1 Q27026627-4AC7BA90-0FB0-40B6-A857-1B69045BDBD8 Q27026665-517DF585-C6DF-459F-9C84-16214A746993 Q27314843-1A5AE5E9-870E-484C-B8EF-89C64B12EC00

P2860

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

http://www.wikidata.org/entity/Q24596055

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Durable complete responses in ...... T-cell transfer immunotherapy

@ast

Durable complete responses in ...... T-cell transfer immunotherapy

@en

Durable complete responses in ...... T-cell transfer immunotherapy

@nl

type

label

Durable complete responses in ...... T-cell transfer immunotherapy

@ast

Durable complete responses in ...... T-cell transfer immunotherapy

@en

Durable complete responses in ...... T-cell transfer immunotherapy

@nl

prefLabel

Durable complete responses in ...... T-cell transfer immunotherapy

@ast

Durable complete responses in ...... T-cell transfer immunotherapy

@en

Durable complete responses in ...... T-cell transfer immunotherapy

@nl

P1433

Q24596055-9857211A-A3F6-41E3-8BE1-5F62CED94675

P1476

Q24596055-A9257C54-1C6D-4DAB-94DE-6F738AA2D524

P2093

Q24596055-2DE0FBF8-0746-44C0-A565-B762A4C49352

Q24596055-4A3139E9-D341-476C-AAC8-8DB84EFC0BCE

Q24596055-4D86BB4F-1002-44F7-86C3-04CBB392DE1C

Q24596055-568AC646-4E2F-46C6-8975-99B8C35E54F4

Q24596055-6EBA0802-F201-47A9-BB92-5668414FB20C

Q24596055-8FB62E8B-06ED-4501-BA59-05FB47E18885

Q24596055-9F3EE1FC-4140-4ECD-A95D-ED4E334569A7

Q24596055-B8C8EE54-53F7-4787-8288-CD61F937EC87

Q24596055-C2B6042B-FB3B-4450-B923-B8A232978DA4

Q24596055-C4F3D658-0B01-446A-99EE-08A6751A0F5C

P2860

Q24596055-0CCF9F2E-6C93-4DC3-B166-2E001D99874D

Q24596055-1E75C02C-B24E-4591-8249-07D4C45BCD1C

Q24596055-1E8E6F95-A979-4DFF-9599-C192830D2CB1

Q24596055-1F79AF6F-473E-4E05-9944-F03BB221065C

Q24596055-2E7BD9B6-3210-4B82-B87B-B37EA623FBEA

Q24596055-35ED8DA9-9E69-45BD-A4A7-E5A7479FE39F

Q24596055-378751D3-3048-4B1C-9F51-337A39E392B5

Q24596055-4E21D5BE-DED5-4424-8045-A1F10915BEAF

Q24596055-50218660-9C9E-431B-B9EB-E95333EC2C5E

Q24596055-599EDB2F-B1FC-4955-82E3-2AD411262C2E

P304

Q24596055-3715B75A-7549-4EE0-AF5D-BD098F0C403E

P31

Q24596055-66C20528-0B22-4FF3-AAF5-3C29804A8EAE

P3181

Q24596055-49358820-29A8-4FEA-9FF6-B2405FCCA192

P356

Q24596055-BE031C27-68F2-4219-969C-1A662EDD6D76

P407

Q24596055-7AE3D1C6-9D9E-4F72-817D-7E5C9D65DFF9

P433

Q24596055-FDAB178B-68A7-4B44-95B7-E7F8F64726E5

P478

Q24596055-0DB91F2C-730A-4E74-92FC-B0DB69486916

P50

Q24596055-6B8489AE-39BA-4C9F-AE45-DFB293094922

P577

Q24596055-77F9F4EB-57F6-48F2-9D1A-940370A40FFF

P698

Q24596055-3043BE24-A436-47E3-A5D7-F8D51EE97A2F

P921

Q24596055-686DE185-846A-4BDE-90F7-3EB46B5E4E98

P932

Q24596055-45484420-8F42-46AC-A18E-E5703B355617

P3181

P356

1078-0432.CCR-11-0116

P1433

Clinical Cancer Research

P1476

Durable complete responses in ...... T-cell transfer immunotherapy

@en

P2093

Carolyn M Laurencot

http://www.w3.org/2001/XMLSchema#string

Deborah E Citrin

http://www.w3.org/2001/XMLSchema#string

Donald E White

http://www.w3.org/2001/XMLSchema#string

Giao Q Phan

http://www.w3.org/2001/XMLSchema#string

James C Yang

http://www.w3.org/2001/XMLSchema#string

John R Wunderlich

http://www.w3.org/2001/XMLSchema#string

Kathleen E Morton

http://www.w3.org/2001/XMLSchema#string

Mark E Dudley

http://www.w3.org/2001/XMLSchema#string

Marybeth S Hughes

http://www.w3.org/2001/XMLSchema#string

Paul F Robbins

http://www.w3.org/2001/XMLSchema#string

P2860

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Adoptive immunotherapy for cancer: building on success

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Cancer immunotherapy: moving beyond current vaccines

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

Cancer regression in patients after transfer of genetically engineered lymphocytes

P304

4550-4557

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1587208

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/1078-0432.CCR-11-0116

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas P. Restifo

P577

2011-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21498393

http://www.w3.org/2001/XMLSchema#string

P921

P932

3131487

http://www.w3.org/2001/XMLSchema#string